logo

For the Inventor, By the Inventor

Laval, Canada

Pierre A Hamel

This inventor holds 28 USPTO granted patents and 1 EPO patent, primarily in PDE4 Inhibitors. Top assignees: Merck Frosst Canada, Inc., Merck Frosst Canada & Co., Merck + Co., Inc.. Active years: 1980-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre A Hamel. Retrieved from https://idiyas.com/inventor/pierre-a-hamel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 28

% Patents Active = 89.3


Average Co-Inventor Count = 4.2

ph-index = 10

Forward Citations = 585(Granted Patents)


Location History:

  • Ottawa, CA (1990)
  • Quebec, CA (1991)
  • Vimont, CA (1984 - 1995)
  • Vimont-Lavel, CA (2004)
  • Laval, CA (1980 - 2005)

Company Filing History:

goldMedal17 out of 212 
 
Merck Frosst Canada, Inc.
 patents
silverMedal7 out of 80 
 
Merck Frosst Canada & Co.
 patents
bronzeMedal3 out of 4,770 
 
Merck + Co., Inc.
 patents
4. 1 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
5. 1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1980-2005

Loading Chart...
Loading Chart...
Areas of Expertise:
PDE4 Inhibitors
Tri-Aryl-Substituted-Ethane
Heterosubstituted Pyridine
Cyclooxygenase
Leukotriene Biosynthesis
Prodrugs
Dibenz[b,e][1,4]Oxathiepin
Benzopyran Derivatives
Hydroxamic Acids
Indole Derivatives
Dihydrofurans
28 patents (USPTO):Explore Patents
1. 6841564 - Tri-aryl-substituted-ethane PDE4 inhibitors (2005-01-11),
2. 6743802 - Alkyne-aryl phosphodiesterase-4 inhibitors (2004-06-01),
3. 6677351 - 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors (2004-01-13),
4. 6399636 - Tri-aryl-substituted-ethane PDE4 inhibitors (2002-06-04),
5. 6200993 - Heterosubstituted pyridine derivatives as PDE4 inhibitors (2001-03-13),
6. 6180650 - Heterosubstituted pyridine derivatives as PDE 4 inhibitors (2001-01-30),
7. 6057319 - 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors (2000-05-02),
8. 5710170 - Tri-aryl ethane derivatives as PDE IV inhibitors (1998-01-20),
9. 5698584 - 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors (1997-12-16),
10. 5639780 - N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase (1997-06-17),
11. 5604253 - N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase (1997-02-18),
12. 5576338 - Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis (1996-11-19),
13. 5428060 - Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis (1995-06-27),
14. 5426109 - Phenylnaphthalene hydroxy acids (1995-06-20),
15. 5350744 - Phenylnaphthalene lactones as inhibitors of leukotriene biosynthesis (1994-09-27),

Title: Pierre A. Hamel: A Trailblazer in Pharmaceutical Innovations

Introduction

Pierre A. Hamel, based in Laval, Canada, is a renowned inventor with an impressive portfolio of 27 patents. His contributions to the field of pharmaceuticals have significantly advanced the development of innovative compounds, particularly in the area of phosphodiesterase inhibitors.

Latest Patents

Among his latest inventions are the "Tri-aryl-substituted-ethane PDE4 inhibitors," which describe novel ethanes substituted with a phenyl, a thiazole, and a pyridyl moiety, recognized for their effectiveness as PDE4 inhibitors. Additionally, he has developed "Alkyne-aryl phosphodiesterase-4 inhibitors," showcasing his commitment to tackling complex medical challenges through innovative chemistry.

Career Highlights

Pierre A. Hamel has had an impactful career, particularly during his tenure at Merck Frosst Canada, Inc. and Merck Frosst Canada & Co. His work in these organizations has been pivotal in the discovery and development of new therapeutic agents designed to improve patient outcomes.

Collaborations

Throughout his career, Hamel has collaborated with notable colleagues, including Yves Girard and Yves Ducharme. These partnerships have fostered a creative and productive environment, contributing to groundbreaking advancements in pharmaceutical research.

Conclusion

In conclusion, Pierre A. Hamel stands out as a distinguished inventor in the pharmaceutical industry, with a rich portfolio of patents that showcases his innovative spirit and dedication. His work continues to influence the development of new therapies that hold great promise for the future of medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…